Tilbroquinol

Summary

Tilbroquinol (CHEMBL1788385) is an approved small molecule (ATC P01AA05); indicated across 1 condition including amebiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P01AA05
• Indications: 1 condition
• Chemistry: 238.08 Da · C10H8BrNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1788385
Name	Tilbroquinol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	65592
ATC	P01AA05
Molecular formula	C10H8BrNO
Molecular weight	238.08
InChIKey	JMOVFFLYGIQXMM-UHFFFAOYSA-N

SMILES: CC1=CC(=C(C2=C1C=CC=N2)O)Br

IUPAC name: 7-bromo-5-methylquinolin-8-ol

Also known as: Tilbroquinol, tilbroquinol, TILBROQUINOL

Patent coverage: 45 distinct patent families (138 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 128 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
amebiasis	4	MONDO:0005644	EFO:0007144

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).